Diligence memo · auto-generated · as of July 2, 2026
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Rivus Pharmaceuticals, Inc. operates in Pharmaceuticals, based in CHARLOTTESVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Rivus Pharmaceuticals, Inc. has raised $223M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $66M on 2024-08-09.
Most recent recorded round closed around 2025-01-07.
Valuation (modeled)modeled
Provath models Rivus Pharmaceuticals, Inc. at approximately $416M (range $185M–$589M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.78× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (26 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 18 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 79% of those peers.
Closest niche peers: BlossomHill Therapeutics, Inc., Sparrow Pharmaceuticals, Inc., Arthrosi Therapeutics, Inc., Altesa BioSciences, Inc., Mirum Pharmaceuticals, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.